Clinical Trials
4
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)Safety, Tolerability, and Pharmacokinetics of IRL201104 in Healthy Volunteers
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Revolo Biotherapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT05921591
- Locations
- 🇺🇸
Revolo Phase I site, Los Angeles, California, United States
Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Revolo Biotherapeutics
- Target Recruit Count
- 63
- Registration Number
- NCT05098522
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
🇬🇧King's College London, London, United Kingdom
A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis
- First Posted Date
- 2021-10-20
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Revolo Biotherapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT05084963
- Locations
- 🇺🇸
Revolo Investigational Site, Salt Lake City, Utah, United States
Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- Revolo Biotherapeutics
- Target Recruit Count
- 18
- Registration Number
- NCT04748536
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
News
Revolo Bio's '1104 Shows Promise in Resetting Immune Response in Allergic Diseases
Revolo Biotherapeutics' '1104 targets antigen-presenting cells, shifting the immune system from a pro-inflammatory to a homeostatic state, potentially inducing remission in allergic conditions.